Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation

• Type of Material: Article
• Authors: Elizabeth Stenger, Emory University; Lakshmanan Krishnamurti, Emory University; Jacques Galipeau, Emory University
• Language: English
• Date: 2015-12-16
• Publisher: BioMed Central
• Publication Version: Final Published Version
• Copyright Statement: © Stenger et al. 2015
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1186/s12865-015-0135-7
• Title of Journal or Parent Work: BMC Immunology
• ISSN: 1471-2172
• Volume: 16
• Issue: 1
• Start Page: 74
• End Page: 74
• Grant/Funding Information: This work was supported by the CHOA Center for Transplantation and Immune-mediated Disorders Pilot Grant (EOS), ACTSI KL2-Mentored Clinical and Translational Research Program (EOS), and the National Institutes of Health grant KL2TR000455 (EOS).
• Keywords: CD34(+) CELLS; NOD/SCID MICE; BONE-MARROW; Immunology; HEMATOLOGIC MALIGNANCY PATIENTS; GRAFT FAILURE; PROMOTE ENGRAFTMENT; CORD BLOOD TRANSPLANTATION; VERSUS-HOST-DISEASE; Science & Technology; ENHANCE ENGRAFTMENT; Life Sciences & Biomedicine; STEM-CELLS
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Immunology

Abstract

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and to promote hematopoiesis. These dual effects make MSCs attractive for use as cellular therapy in hematopoietic cell transplantation (HCT). MSCs can be used peri-HCT or pre-engraftment to modulate immune reconstitution, promoting hematopoietic stem cell (HSC) engraftment and/or preventing graft-versus-host disease (GVHD). Pre-clinical studies have demonstrated that MSCs can potentiate HSC engraftment and prevent GVHD in a variety of animal models. Clinical trials have been small and largely non-randomized but have established safety and early evidence of efficacy, supporting the need for larger randomized trials.